Category: Disclosures

[Disclosure] Celltrion (068270) – Execution of License-in Agreement for Novel Drug Candidates for Rare Autoimmune Diseases / 2025-11-04

November 4, 2025August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has entered into a global license-in agreement worth up to USD 744.0M (approx. KRW 1.06T) with US-based Kaigene, Inc. for two novel drug candidates targeting rare autoimmune diseases. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Phase…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Provisional Earnings Release (Consolidated Basis) (Correction) / 2025-11-04

November 4, 2025August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has issued a corrected provisional earnings release for Q3 2025 on a consolidated basis, updating revenue to KRW 1.03T (+16.67% YoY) and operating profit to KRW 301.4B (+45.13% YoY) while populating all detailed net income metrics. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s…

Disclosures, Bio & Healthcare

[Disclosure] Hyundai Motor (005380) – Investor Relations (IR) Announcement / 2025-11-03

November 3, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hyundai Motor will hold an overseas Non-Deal Roadshow (NDR) for major international institutional investors starting November 10, 2025, across the US, Asia, and Europe, to present its Q3 2025 financial results and discuss key investor interests. 📊 [Key Disclosure Content & Financial Highlights] 1. Event Overview…

Disclosures, Automotive

[Disclosure] Hyundai Motor (005380) – Provisional Sales Results / 2025-11-03

November 3, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hyundai Motor sold a total of 351,753 vehicles globally in October 2025, representing a 6.9% decrease compared to the same period last year. 📊 [Key Disclosure Content & Financial Highlights] 1. Monthly Sales Volume for October 2025 (Unit: Vehicles, %) 2. Cumulative Sales Volume for Jan-Oct…

Automotive, Disclosures

[Disclosure] Hanwha Aerospace (012450) – Provisional Consolidated Financial Results / 2025-11-03

November 3, 2025August 9, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 Executive Summary Hanwha Aerospace reported its provisional Q3 2025 consolidated results, posting KRW 6.49T in sales (+146.5% YoY) and KRW 856.4B in operating profit (+79.5% YoY). Cumulative 9-month operating profit reached KRW 2.28T. 📊 [Key Disclosure Contents & Summary of Figures] [Q3 2025 Quarterly Results (Unit: 100M KRW,…

Disclosures, Defense

[Disclosure] Hanwha Aerospace (012450) – Change in Representative Director / 2025-11-03

November 3, 2025August 9, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 Executive Summary Hanwha Aerospace disclosed a change in its leadership structure from three representative directors (Dong-Kwan Kim, Jae-Il Son, Michael Coulter, each with independent representative authority) to two (Dong-Kwan Kim, Jae-Il Son) following the resignation of Representative Director Michael Coulter. 📊 [Key Disclosure Contents & Summary of Figures]…

Disclosures, Defense

[Disclosure] Celltrion (068270) – Execution of Joint R&D and License Agreement for PD-1 x VEGF x IL-2v Tri-functional Fusion Protein / 2025-10-31

October 31, 2025August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has entered into a joint R&D and licensing agreement with Korean biotech MUSTBIO for the development of a PD-1 x VEGF x IL-2v tri-functional fusion protein novel drug, with a total potential deal value of up to KRW 712.5B. 📊 [Key Disclosure Details & Financial…

Disclosures, Bio & Healthcare

[Disclosure] Hanwha Systems (272210) – Investor Relations (IR) Holding / 2025-10-31

October 31, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems will hold an Investor Relations (IR) event from November 3 to November 5, 2025, conducting 1:1 meetings with major domestic institutional investors to present its Q3 2025 business performance and address Q&A. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up…

Disclosures, Defense

[Disclosure] Hanwha Systems (272210) – Provisional Sales Results / 2025-10-31

October 31, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary In Q3 2025, Hanwha Systems recorded sales of approximately KRW 807.7B, up 26.41% year-on-year. However, operating profit declined by 62.67% year-on-year to KRW 22.5B, while net profit was recorded at KRW 151.8B. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Disclosures, Defense

[Disclosure] Hanmi Semiconductor (042700) – Provisional Operating Results (Consolidated) / 2025-10-31

October 31, 2025July 31, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary For Q3 2025, Hanmi Semiconductor reported provisional consolidated revenue of KRW 166.23B and operating profit of KRW 67.82B, showing a decline compared to the previous quarter and the same period last year; however, cumulative revenue and operating profit through Q3 grew by over 20% year-over-year. 📊…

Semiconductors, Disclosures